journal
https://read.qxmd.com/read/38872458/migraine-in-women
#1
EDITORIAL
Arathi Nandyala, Rebecca Burch, Rashmi Halker Singh
No abstract text is available yet for this article.
June 14, 2024: Headache
https://read.qxmd.com/read/38860510/pediatric-post-dural-puncture-headache-and-paraplegia
#2
JOURNAL ARTICLE
Wouter I Schievink, Marcel M Maya, Rachelle B Taché, Corey T Walker
A cerebrospinal fluid (CSF) leak developed in a 14-year-old girl and a 12-year-old boy following a diagnostic lumbar puncture. Two days and sixteen years later, respectively, paraplegia developed due to a functional disorder. Imaging revealed an extensive extradural CSF collection in both patients and digital subtraction myelography was required to pinpoint the exact site of a ventral dural puncture hole where the lumbar spinal needle had gone "through and through" the dural sac. The CSF leak was complicated by cortical vein thrombosis in one patient...
June 11, 2024: Headache
https://read.qxmd.com/read/38860505/are-there-differences-between-patients-with-unifocal-nummular-headache-and-those-who-progress-to-bifocal-nummular-headache-a-retrospective-observational-study
#3
JOURNAL ARTICLE
Gonçalo Cabral, Miguel Serôdio, Danna Krupka, Vitor Mendes Ferreira, Sofia Calado, Miguel V Baptista
OBJECTIVES: This retrospective observational cohort study aimed to compare clinical characteristics and treatment responses in patients exclusively experiencing unifocal nummular headache (NH) with those who develop the bifocal variant. METHODS: A retrospective study was conducted on patients diagnosed with NH who attended a neurology (headache) outpatient clinic between January 2018 and December 2022. The cohort was divided into two groups: Group 1, exclusive unifocal NH; and Group 2, those developing a secondary focal area of pain, i...
June 11, 2024: Headache
https://read.qxmd.com/read/38842246/mechanisms-for-mindfulness-in-migraine-does-catastrophizing-matter
#4
EDITORIAL
Rebecca Erwin Wells, Nathaniel O'Connell, Mia T Minen
No abstract text is available yet for this article.
June 6, 2024: Headache
https://read.qxmd.com/read/38837724/retraction-effectiveness-of-anti-cgrp-monoclonal-antibodies-for-persistent-headaches-in-patients-with-idiopathic-intracranial-hypertension
#5
(no author information available yet)
Retraction: Frerichs, L., Nandy, K., Friedman, D.I. (2022) P-119. Effectiveness of anti-CGRP monoclonal antibodies for persistent headaches in patients with idiopathic intracranial hypertension [Abstract] Headache, v 62.S1: 106. https://doi.org/10.1111/head.14317. The above abstract from American Headache Society 64th Annual Scientific Meeting June 9-12, 2022 Denver, Colorado, published online on 20 May 2022, in Wiley Online Library (https://onlinelibrary.wiley.com/), has been retracted by agreement between the authors, the journal Editor in Chief, Amy A...
June 4, 2024: Headache
https://read.qxmd.com/read/38837259/early-effect-of-onabotulinumtoxina-on-eeg-based-functional-connectivity-in-patients-with-chronic-migraine-a-pilot-study
#6
JOURNAL ARTICLE
Matteo Conti, Roberta Bovenzi, Maria Giuseppina Palmieri, Fabio Placidi, Alessandro Stefani, Nicola Biagio Mercuri, Maria Albanese
OBJECTIVE: In this pilot prospective cohort study, we aimed to evaluate, using high-density electroencephalography (HD-EEG), the longitudinal changes in functional connectivity (FC) in patients with chronic migraine (CM) treated with onabotulinumtoxinA (OBTA). BACKGROUND: OBTA is a treatment for CM. Several studies have shown the modulatory action of OBTA on the central nervous system; however, research on migraine is limited. METHODS: This study was conducted at the Neurology Unit of "Policlinico Tor Vergata," Rome, Italy, and included 12 adult patients with CM treated with OBTA and 15 healthy controls (HC)...
June 4, 2024: Headache
https://read.qxmd.com/read/38828836/the-2023-protocol-for-update-to-acute-treatment-of-adults-with-migraine-in-the-emergency-department-the-american-headache-society-evidence-assessment-of-parenteral-pharmacotherapies
#7
JOURNAL ARTICLE
Jennifer Robblee, Xurong Rachel Zhao, Mia T Minen, Benjamin W Friedman, Miguel A Cortel-LeBlanc, Achelle Cortel-LeBlanc, Serena L Orr
OBJECTIVES: The primary objective of this proposed guideline is to update the prior 2016 guideline on parenteral pharmacotherapies for the management of adults with a migraine attack in the emergency department (ED). METHODS: We will conduct an updated systematic review and meta-analysis using the 2016 guideline methodology to provide clinical recommendations. The same search strategy will be used for studies up to 2023, with a new search strategy added to capture studies of nerve blocks and sphenopalatine blocks...
June 3, 2024: Headache
https://read.qxmd.com/read/38828670/evaluating-patient-and-family-preferences-for-acute-and-preventive-pediatric-headache-treatment
#8
JOURNAL ARTICLE
Elise G Martin, Jonathan Kuziek, Jananee Rasiah, Serena L Orr
OBJECTIVE: To describe acute and preventive treatment preferences among youth with migraine and their parents/guardians, and to describe the degree of youth-parent/guardian preference agreement. BACKGROUND: Headache disorders are common in youth, but little is known about patient and family preferences for headache treatments and outcomes. METHODS: In this cross-sectional survey, a headache treatment preferences questionnaire was co-created with stakeholders, piloted, and distributed to consenting youth with migraine aged 9-18 years and parents/guardians at a tertiary care headache clinic in western Canada...
June 3, 2024: Headache
https://read.qxmd.com/read/38828666/basic-science-prize-award-2023
#9
EDITORIAL
Edina Szabo, Patricia A Olson
No abstract text is available yet for this article.
June 3, 2024: Headache
https://read.qxmd.com/read/38800847/cardiovascular-safety-of-dihydroergotamine-mesylate-delivered-by-precision-olfactory-delivery-inp104-for-the-acute-treatment-of-migraine
#10
JOURNAL ARTICLE
Rima M Dafer, Gretchen E Tietjen, John F Rothrock, Robert E Vann, Stephen B Shrewsbury, Sheena K Aurora
OBJECTIVE: To report the cardiovascular (CV) safety of dihydroergotamine mesylate (DHE) administered by precision olfactory delivery (INP104) from two clinical trials. BACKGROUND: Although the absolute risk is low, migraine is associated with an increased risk of CV events. DHE is a highly effective acute treatment for migraine, but due to its theoretical risk of promoting arterial vasoconstriction, DHE is contraindicated in patients with CV disease or an unfavorable risk factor profile...
May 27, 2024: Headache
https://read.qxmd.com/read/38785411/a-retrospective-review-of-sex-differences-of-white-matter-hyperintensities-in-brain-mri-of-patients-with-migraine
#11
JOURNAL ARTICLE
Ye Su, Victoria Q Tay, Satinderpal Singh, Megan C Leary, Vitaliy Koss, Hope M Kincaid, Hussam A Yacoub, John Castaldo
OBJECTIVES: The primary objective of this study was to evaluate the prevalence of white matter hyperintensities (WMHs) in patients who experience migraine and compare findings between adult male and female patients. Specific symptoms and comorbidities also were analyzed to determine whether they were associated with WMH prevalence or the sex of patients with migraine. We hypothesized that females would have a higher prevalence of WMHs, experience more frequent and more severe migraine headaches, and be more likely to have certain comorbidities associated with migraine than males...
May 24, 2024: Headache
https://read.qxmd.com/read/38785395/german-language-adaptation-of-the-cogniphobia-scale-for-headache-disorders-cs-hd-and-development-of-a-new-short-form-cs-hd-6
#12
JOURNAL ARTICLE
Timo Klan, Anne-Kathrin Bräscher, Elizabeth K Seng, Charly Gaul, Michael Witthöft
OBJECTIVE: This study is part of the ODIN-migraine (Optimization of Diagnostic Instruments in migraine) project. It is a secondary, a priori analysis of previously collected data, and aimed to assess the psychometric properties and factor structure of the Cogniphobia Scale for Headache Disorders (CS-HD). We aimed to construct a German-language version and a short version. BACKGROUND: Cogniphobia is the fear and avoidance of cognitive exertion, which the patient believes triggers or exacerbates headache...
May 24, 2024: Headache
https://read.qxmd.com/read/38785393/effect-of-erenumab-on-the-reversion-from-chronic-migraine-to-episodic-migraine-in-an-asian-population-a-post-hoc-analysis-of-the-dragon-study
#13
JOURNAL ARTICLE
Shuu-Jiun Wang, Byung-Kun Kim, Hebo Wang, Jiying Zhou, Qi Wan, Tingmin Yu, Yajun Lian, Michal Arkuszewski, Laurent Ecochard, Josefin Snellman, Shihua Wen, Fangfang Yin, Zheng Li, Wendy Su, Shengyuan Yu
BACKGROUND: Erenumab is a fully human monoclonal antibody that selectively targets the calcitonin gene-related peptide receptor. It has been proven to be safe and efficacious in patients with episodic migraine (EM) and chronic migraine (CM) as demonstrated in phase 2 and 3 clinical trials including patients from Europe, Japan, and the United States. Reversion from CM to EM, as indicated by a reduction in the frequency of headache days, is an important indicator for efficacy outcome, though it has not been analyzed widely in patients with CM to date...
May 24, 2024: Headache
https://read.qxmd.com/read/38785386/a-real-world-prospective-observational-study-of-eptinezumab-in-asian-patients-with-migraine
#14
JOURNAL ARTICLE
Yi Jing Zhao, Jonathan Jia Yuan Ong, Sumit Kumar Sonu, Jiaojiao Dang, Chai Ching Ng, Keira Joann Herr, Rohini Bose, Yasmin Idu Jion
OBJECTIVE: To evaluate the real-world effectiveness of eptinezumab for migraine prevention in Asian patients. BACKGROUND: Eptinezumab is a monoclonal antibody that targets calcitonin gene-related peptide (CGRP), a potent vasodilator with an important role in migraine pathophysiology. Although there is robust clinical evidence from pivotal Phase 3 placebo-controlled trials of the efficacy of eptinezumab for migraine prevention, there are limited data on the real-world effectiveness of eptinezumab in Asian patient cohorts...
May 24, 2024: Headache
https://read.qxmd.com/read/38785385/celebrating-headache-s-2024-graduating-class-of-assistant-editors
#15
EDITORIAL
Sarah M Bobker
No abstract text is available yet for this article.
May 24, 2024: Headache
https://read.qxmd.com/read/38785227/machine-learning-identifies-factors-most-associated-with-seeking-medical-care-for-migraine-results-of-the-overcome-us-study
#16
JOURNAL ARTICLE
Sait Ashina, E Jolanda Muenzel, Robert A Nicholson, Anthony J Zagar, Dawn C Buse, Michael L Reed, Robert E Shapiro, Susan Hutchinson, Eric M Pearlman, Richard B Lipton
OBJECTIVE: Utilize machine learning models to identify factors associated with seeking medical care for migraine. BACKGROUND: Migraine is a leading cause of disability worldwide, yet many people with migraine do not seek medical care. METHODS: The web-based survey, ObserVational survey of the Epidemiology, tReatment and Care Of MigrainE (US), annually recruited demographically representative samples of the US adult population (2018-2020). Respondents with active migraine were identified via a validated diagnostic questionnaire and/or a self-reported medical diagnosis of migraine, and were then asked if they had consulted a healthcare professional for their headaches in the previous 12 months (i...
May 24, 2024: Headache
https://read.qxmd.com/read/38780360/functional-impairment-of-chronic-migraine-with-medication-overuse-secondary-analysis-from-the-medication-overuse-treatment-strategy-mots-trial
#17
JOURNAL ARTICLE
Samantha C Shao, Joseph Hentz, Patti Shank, Michael Leonard, David W Dodick, Todd J Schwedt
BACKGROUND: Chronic migraine exerts substantial negative impacts on daily functioning. Efforts to manage impaired functioning may result in medication overuse, which contributes to the worsening profile and chronification of migraine. The Migraine Functional Impact Questionnaire (MFIQ) is a recently developed measure assessing the impact of migraine on physical, social, and emotional function. OBJECTIVE: The objective of this analysis was to assess changes in MFIQ scores following initiation or modification of migraine preventive medication and determine if changes in function are associated with changes in other aspects of migraine burden, such as headache frequency, headache intensity, and symptoms of anxiety and depression...
May 23, 2024: Headache
https://read.qxmd.com/read/38780233/the-critical-role-of-neuroimaging-in-hemicrania-continua-a%C3%A2-systematic-review-and-case-series
#18
REVIEW
Hasna Yildiz Goksel, Seyma Bilgin, Kathleen Digre, Melissa M Cortez, Seniha N Ozudogru
BACKGROUND: Hemicrania continua is a primary unilateral headache characterized by ipsilateral parasympathetic and sympathetic autonomic features. A key diagnostic criterion is its dramatic response to indomethacin treatment; however, various vascular or structural abnormalities have been reported to cause secondary hemicrania continua, presenting with clinical features similar to those of the primary headache presentation. OBJECTIVE: We reviewed the literature to compile secondary hemicrania continua cases, highlighting the importance of imaging during the evaluation...
May 23, 2024: Headache
https://read.qxmd.com/read/38780214/radiological-features-of-patients-with-headache-as-a-presenting-symptom-of-neurosarcoidosis
#19
JOURNAL ARTICLE
Selina Mahmood, Yamin Sallowm, Muhammad Affan, Lonni Schultz, Mirela Cerghet, Ashhar Ali
OBJECTIVE: To describe the radiological features of patients with headache as a presenting symptom of neurosarcoidosis. BACKGROUND: Neurologic complications occur in approximately 5%-10% of patients with sarcoidosis, and approximately 50% of these patients have neurologic deficits at the time sarcoidosis is first diagnosed. A wide spectrum of central and peripheral nervous system clinical manifestations may be observed, including cranial nerve palsies, sensory and/or motor deficits, and headache...
May 23, 2024: Headache
https://read.qxmd.com/read/38779974/beyond-aura-understanding-migraine-as-a-cycling-pan-sensory-threshold-disease
#20
EDITORIAL
Arne May
No abstract text is available yet for this article.
May 23, 2024: Headache
journal
journal
25525
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.